Fimasartan (BioDeep_00000858950)

   


代谢物信息卡片


Fimasartan

化学式: C27H31N7OS (501.2310676)
中文名称: 非马沙坦
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C
InChI: InChI=1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32)

描述信息

C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
Fimasartan (BR-A-657) is a non-peptide antagonist of the angiotensin receptor AT1, used to study hypertension and heart failure.

同义名列表

2 个代谢物同义名

Fimasartan; BR-A-657



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Weaam Abbas, Murooj Altemimi, Heider Qassam, Ahmed Abdul Hameed, Qassim Zigam, Lamaan Abbas, Majid Jabir, Najah Hadi. Fimasartan ameliorates renal ischemia reperfusion injury via modulation of oxidative stress, inflammatory and apoptotic cascades in a rat model. Journal of medicine and life. 2022 Feb; 15(2):241-251. doi: 10.25122/jml-2021-0154. [PMID: 35419091]
  • Poonam Giri, Vipul Joshi, Shyamkumar Giri, Prashant Delvadia, Mukul R Jain. Simultaneous determination of sacubitrilat and fimasartan in rat plasma by a triple quad liquid chromatography-tandem mass spectrometry method utilizing electrospray ionization in positive mode. Biomedical chromatography : BMC. 2021 Feb; 35(2):e4981. doi: 10.1002/bmc.4981. [PMID: 32895916]
  • Seung-Jun Lee, Jaewon Oh, Sung-Jin Hong, In-Jeong Cho, Su Rae Kim, Jae-Sun Uhm, Chi Young Shim, Hyuk-Jae Chang, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Sungha Park, Sang-Hak Lee, Geu Ru Hong, Young-Guk Ko, Donghoon Choi. Effectiveness of Fimasartan and Rosuvastatin Combination Treatment in Hypertensive Patients With Dyslipidemia. Clinical therapeutics. 2020 06; 42(6):1058-1066.e3. doi: 10.1016/j.clinthera.2020.03.019. [PMID: 32376036]
  • Jun Gi Hwang, Kyung-Sang Yu, SeungHwan Lee. Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets. Drug design, development and therapy. 2020; 14(?):1953-1961. doi: 10.2147/dddt.s233732. [PMID: 32546962]
  • Woo Youl Kang, Hae Won Lee, Mi-Ri Gwon, Seungil Cho, Wang-Seob Shim, Kyung-Tae Lee, Dong Heon Yang, Sook Jin Seong, Young-Ran Yoon. A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers. Drug design, development and therapy. 2020; 14(?):2101-2111. doi: 10.2147/dddt.s248205. [PMID: 32546973]
  • Jong-Ho Kim, I-Rang Lim, Hyung Joon Joo, Chi-Yeon Park, Seung-Cheol Choi, Han Saem Jeong, Soon Jun Hong. Fimasartan reduces neointimal formation and inflammation after carotid arterial injury in apolipoprotein E knockout mice. Molecular medicine (Cambridge, Mass.). 2019 07; 25(1):33. doi: 10.1186/s10020-019-0095-0. [PMID: 31307370]
  • Fabio Angeli, Paolo Verdecchia, Monica Trapasso, Marina Pane, Sara Signorotti, Gianpaolo Reboldi. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives. Expert opinion on drug metabolism & toxicology. 2018 May; 14(5):533-541. doi: 10.1080/17425255.2018.1468435. [PMID: 29676941]
  • Mun Hee Choi, Jin Soo Lee, Sung Eun Lee, Seong-Joon Lee, Dukyong Yoon, Rae Woong Park, Ji Man Hong. Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial. Scientific reports. 2018 01; 8(1):1556. doi: 10.1038/s41598-018-19998-4. [PMID: 29367614]
  • Jieon Lee, Su-Jin Rhee, SeungHwan Lee, Kyung-Sang Yu. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians. Drug design, development and therapy. 2018; 12(?):787-794. doi: 10.2147/dddt.s145339. [PMID: 29670335]
  • Woo Youl Kang, Sook Jin Seong, Boram Ohk, Mi-Ri Gwon, Bo Kyung Kim, Seungil Cho, Wang-Seob Shim, Kyung-Tae Lee, Eun Hee Kim, Dong Heon Yang, Hae Won Lee, Young-Ran Yoon. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects. Drug design, development and therapy. 2018; 12(?):3607-3615. doi: 10.2147/dddt.s161917. [PMID: 30464392]
  • Minkyung Oh, Jong-Lyul Ghim, Sung-Eun Park, Eun-Young Kim, Jae-Gook Shin. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects. Drug design, development and therapy. 2018; 12(?):1157-1164. doi: 10.2147/dddt.s164215. [PMID: 29780236]
  • Jang-Young Kim, Jung-Woo Son, Sungha Park, Tea-Hyun Yoo, Yong-Jin Kim, Dong-Ryeol Ryu, Ho Jun Chin. FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. Trials. 2017 Dec; 18(1):632. doi: 10.1186/s13063-017-2375-8. [PMID: 29284530]
  • Jürgen B Bulitta, Soo Heui Paik, Yong Ha Chi, Tae Hwan Kim, Soyoung Shin, Cornelia B Landersdorfer, Yuanyuan Jiao, Rajbharan Yadav, Beom Soo Shin. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2017 Sep; 107(?):32-44. doi: 10.1016/j.ejps.2017.06.008. [PMID: 28599987]
  • Tae Hwan Kim, Min Gi Kim, Soyoung Shin, Yong-Ha Chi, Soo-Heui Paik, Joo-Han Lee, Sun Dong Yoo, Yu Seok Youn, Jürgen B Bulitta, Sang Hoon Joo, Seok Won Jeong, Kwon-Yeon Weon, Beom Soo Shin. Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats. BMC pharmacology & toxicology. 2016 07; 17(1):35. doi: 10.1186/s40360-016-0080-y. [PMID: 27459959]
  • Jaelim Cho, Changsoo Kim, Dae Ryong Kang, Jeong Bae Park. Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: K-MetS Study. Medicine. 2016 Jul; 95(28):e4177. doi: 10.1097/md.0000000000004177. [PMID: 27428212]
  • Ji-Yoon Lee, Young Jae Choi, Soo Jin Oh, Yong Ha Chi, Soo Heui Paik, Ki Ho Lee, Jae-Kyung Jung, Chang Seon Ryu, Kwon-Bok Kim, Dong-Hyun Kim, Young-Ran Yoon, Sang Kyum Kim. Characterization of fimasartan metabolites in human liver microsomes and human plasma. Xenobiotica; the fate of foreign compounds in biological systems. 2016; 46(1):40-51. doi: 10.3109/00498254.2015.1047429. [PMID: 26068523]
  • Namyi Gu, Joo-Youn Cho, Kwang-Hee Shin, In-Jin Jang, Moo-Yong Rhee. The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan. Drug design, development and therapy. 2016; 10(?):1525-31. doi: 10.2147/dddt.s94694. [PMID: 27143858]
  • Seo Hyun Yoon, Seul Oh, Hwa Suk Kim, SoJeong Yi, Kyung-Sang Yu, In-Jin Jang, Joo-Youn Cho. Validated LC-MS/MS Assay for the Quantitative Determination of Fimasartan in Human Plasma: Application to Pharmacokinetic Studies. Journal of chromatographic science. 2015 Sep; 53(8):1250-6. doi: 10.1093/chromsci/bmu219. [PMID: 25616988]
  • Tae Hwan Kim, Soyoung Shin, Cornelia B Landersdorfer, Yong Ha Chi, Soo Heui Paik, Jayhyuk Myung, Rajbharan Yadav, Stefan Horkovics-Kovats, Jürgen B Bulitta, Beom Soo Shin. Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans. The AAPS journal. 2015 Sep; 17(5):1210-23. doi: 10.1208/s12248-015-9764-2. [PMID: 25990964]
  • Soojeong Kim, Sung Jun Kim, Hye Eun Yoon, Sungjin Chung, Bum Soon Choi, Cheol Whee Park, Seok Joon Shin. Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2. International journal of medical sciences. 2015; 12(11):891-904. doi: 10.7150/ijms.13187. [PMID: 26640409]
  • Ji Yeon Hyun, Hyun-Ju Kim, Mi-Ri Gwon, Hae Won Lee, Sook Jin Seong, Young-Ran Yoon. Fully Validated Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Fimasartan in Human Plasma. Analytical sciences : the international journal of the Japan Society for Analytical Chemistry. 2015; 31(12):1335-9. doi: 10.2116/analsci.31.1335. [PMID: 26656827]
  • Tae Hwan Kim, Soyoung Shin, Mohammad Bashir, Yong Ha Chi, Soo Heui Paik, Joo Han Lee, Hyuk Joon Choi, Jin Ho Choi, Sun Dong Yoo, Jürgen B Bulitta, Eunsook Ma, Sang Hoon Joo, Beom Soo Shin. Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats. Xenobiotica; the fate of foreign compounds in biological systems. 2014 Oct; 44(10):913-25. doi: 10.3109/00498254.2014.915359. [PMID: 24786684]
  • Seokuee Kim, Jongtae Lee, Donghoon Shin, Kyoung Soo Lim, Yon Su Kim, In-Jin Jang, Kyung-Sang Yu. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study. Drug design, development and therapy. 2014; 8(?):1723-31. doi: 10.2147/dddt.s68784. [PMID: 25336916]
  • Choon Ok Kim, Hae Wan Lee, Eun Sil Oh, Sook Jin Seong, Do Young Kim, Joomi Lee, Sang-Hoon Ahn, Young-Ran Yoon, Chang-Min Cho, Min Soo Park. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan. Journal of cardiovascular pharmacology. 2013 Dec; 62(6):524-9. doi: 10.1097/fjc.0000000000000010. [PMID: 24084213]
  • Jung Won Kim, SoJeong Yi, Tae-Eun Kim, Kyoung Soo Lim, Seo Hyun Yoon, Joo-Youn Cho, Min Goo Lee, Im-Sook Song, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. Journal of clinical pharmacology. 2013 Jan; 53(1):75-81. doi: 10.1177/0091270011433328. [PMID: 23400746]
  • Namyi Gu, Bo-Hyung Kim, Kyoung Soo Lim, Sung Eun Kim, Won Seok Nam, Seo Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial. Clinical therapeutics. 2012 Jul; 34(7):1592-600. doi: 10.1016/j.clinthera.2012.06.004. [PMID: 22727611]
  • Hyewon Jeon, Kyoung Soo Lim, Kwang-Hee Shin, JaeWoo Kim, Seo Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers. Journal of cardiovascular pharmacology. 2012 Jan; 59(1):84-91. doi: 10.1097/fjc.0b013e318237389e. [PMID: 21934629]
  • Kwang-Hee Shin, Tae-Eun Kim, Sung Eun Kim, Min Goo Lee, Im-Sook Song, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang, Sang-Goo Shin, Kyung-Sang Yu. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. Journal of cardiovascular pharmacology. 2011 Nov; 58(5):492-9. doi: 10.1097/fjc.0b013e31822b9092. [PMID: 21765368]
  • Beom Soo Shin, Tae Hwan Kim, Soo Heui Paik, Yong Ha Chi, Joo Han Lee, Hyun Kwang Tan, Yohan Choi, Minki Kim, Sun Dong Yoo. Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. Biomedical chromatography : BMC. 2011 Nov; 25(11):1208-14. doi: 10.1002/bmc.1592. [PMID: 21268050]
  • Hae Won Lee, Mi-Sun Lim, Sook Jin Seong, Joomi Lee, Jeonghyeon Park, Jeong Ju Seo, Joo-Youn Cho, Kyung-Sang Yu, Young-Ran Yoon. Effect of age on the pharmacokinetics of fimasartan (BR-A-657). Expert opinion on drug metabolism & toxicology. 2011 Nov; 7(11):1337-44. doi: 10.1517/17425255.2011.618835. [PMID: 21950382]
  • Yong Ha Chi, Howard Lee, Soo Heui Paik, Joo Han Lee, Byoung Wook Yoo, Ji Han Kim, Hyun Kwang Tan, Sang Lin Kim. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2011 Oct; 11(5):335-46. doi: 10.2165/11593840-000000000-00000. [PMID: 21910510]
  • SoJeong Yi, Tae-Eun Kim, Seo Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. Journal of cardiovascular pharmacology. 2011 Jun; 57(6):682-9. doi: 10.1097/fjc.0b013e31821795d0. [PMID: 21394036]